Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia.

Adiels M, Taskinen MR, Björnson E, Andersson L, Matikainen N, Söderlund S, Kahri J, Hakkarainen A, Lundbom N, Sihlbom C, Thorsell A, Zhou H, Pietiläinen KH, Packard C, Borén J

Diabetes, obesity & metabolism8 May 2019Cited by 42 (Europe PMC)

PMID30972934DOI10.1111/dom.13744PepBankPUB-30972934

Source link PubMedAsk about this study

Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialEfficacy outcome
In subjects with type 2 diabetes, 16 weeks of liraglutide significantly reduced the apoC-III secretion rate.
In plain wordsIn people with type 2 diabetes, 16 weeks of liraglutide lowered how fast the body makes apoC-III, a fat-carrying protein.
Peptide
Liraglutide
Outcome
DecreaseapoC-III secretion rate after liraglutide
Study
n: not reported in source
Comparator
Before liraglutide
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
apoC-III secretion rate
561 mg/d
after liraglutide
apoC-III secretion rate
652 mg/d
before liraglutide
Source sentences
Summary
Improved glycaemic control by liraglutide therapy for 16 weeks significantly reduced apoC-III secretion rate (561 ± 198 vs. 652 ± 196 mg/d, P = 0.03)
1 context sentence(design, population, supporting numbers)
Summary · context
We compared apoC-III kinetics in two situations: in subjects with type 2 diabetes before and after liraglutide therapy, and in type 2 diabetic subjects with matched body mass index (BMI) non-diabetic subjects.
Report a problemFND-3097293401
02HumanNon-randomized trialEfficacy outcome
In subjects with type 2 diabetes, 16 weeks of liraglutide significantly reduced apoC-III levels.
In plain wordsIn people with type 2 diabetes, 16 weeks of liraglutide lowered apoC-III levels, a fat-carrying protein, compared with before treatment.
Peptide
Liraglutide
Outcome
DecreasePlasma apoC-III level after liraglutide
Study
n: not reported in source
Comparator
Before liraglutide
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
apoC-III level
10 mg/dL
after liraglutide
apoC-III level
11.7 mg/dL
before liraglutide
Source sentences
Summary
Improved glycaemic control by liraglutide therapy for 16 weeks significantly reduced apoC-III secretion rate (561 ± 198 vs. 652 ± 196 mg/d, P = 0.03) and apoC-III levels (10.0 ± 3.8 vs. 11.7 ± 4.3 mg/dL, P = 0.035) in subjects with type 2 diabetes.
1 context sentence(design, population, supporting numbers)
Summary · context
We compared apoC-III kinetics in two situations: in subjects with type 2 diabetes before and after liraglutide therapy, and in type 2 diabetic subjects with matched body mass index (BMI) non-diabetic subjects.
Report a problemFND-3097293402
03HumanNon-randomized trialMechanism
During liraglutide therapy, the change in apoC-III secretion rate was significantly associated with the improvement in indices of glucose control.
In plain wordsDuring liraglutide treatment, a larger fall in apoC-III production went with a larger improvement in blood sugar control.
Peptide
Liraglutide
Outcome
Not applicableAssociation of apoC-III secretion change with glucose control change
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
r
0.67
apoC-III secretion change vs glucose control improvement
Source sentences
Summary
Change in apoC-III secretion rate was significantly associated with the improvement in indices of glucose control (r = 0.67; P = 0.009) and change in triglyceride area under the curve (r = 0.59; P = 0.025).
1 context sentence(design, population, supporting numbers)
Summary · context
We compared apoC-III kinetics in two situations: in subjects with type 2 diabetes before and after liraglutide therapy, and in type 2 diabetic subjects with matched body mass index (BMI) non-diabetic subjects.
Report a problemFND-3097293403
04HumanNon-randomized trialMechanism
During liraglutide therapy, the change in apoC-III secretion rate was significantly associated with the change in triglyceride area under the curve.
In plain wordsDuring liraglutide treatment, a larger fall in apoC-III production went with a larger change in blood triglycerides after a meal.
Peptide
Liraglutide
Outcome
Not applicableAssociation of apoC-III secretion change with triglyceride AUC change
Study
n: not reported in source
Outcome group
Lipids · Metabolic and weight
Studied dose
Dose not stated · 16 weeksAs given in this study (human).
Measurements
r
0.59
apoC-III secretion change vs triglyceride AUC change
Source sentences
Summary
Change in apoC-III secretion rate was significantly associated with the improvement in indices of glucose control (r = 0.67; P = 0.009) and change in triglyceride area under the curve (r = 0.59; P = 0.025).
1 context sentence(design, population, supporting numbers)
Summary · context
We compared apoC-III kinetics in two situations: in subjects with type 2 diabetes before and after liraglutide therapy, and in type 2 diabetic subjects with matched body mass index (BMI) non-diabetic subjects.
Report a problemFND-3097293404

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

05HumanNot a test of Liraglutide aloneObservational studyEfficacy outcome
No liraglutide was given in this comparison: apoC-III secretion rate was higher in subjects with type 2 diabetes than in BMI-matched non-diabetic subjects.
In plain wordsPeople with type 2 diabetes made more apoC-III than people of similar weight without diabetes. This comparison did not involve liraglutide.
Peptide
Liraglutide
Outcome
IncreaseapoC-III secretion rate in type 2 diabetes versus non-diabetic subjects
Study
n: not reported in source
Comparator
BMI-matched non-diabetic subjects
Outcome group
Lipids · Metabolic and weight
Measurements
apoC-III secretion rate
676 mg/d
type 2 diabetes
apoC-III secretion rate
505 mg/d
non-diabetic
Source sentences
Summary
In line with this, the apoC-III secretion rate was higher in subjects with type 2 diabetes compared with BMI-matched non-diabetic subjects (676 ± 208 vs. 505 ± 174 mg/d, P = 0.042).
1 context sentence(design, population, supporting numbers)
Summary · context
We compared apoC-III kinetics in two situations: in subjects with type 2 diabetes before and after liraglutide therapy, and in type 2 diabetic subjects with matched body mass index (BMI) non-diabetic subjects.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3097293405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.